DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Flolan (Epoprostenol Sodium) - Published Studies


Flolan Related Published Studies

Well-designed clinical trials related to Flolan (Epoprostenol)

IVI epoprostenol as salvage therapy in pulmonary arterial hypertension: an Australian perspective. [2011.03]

No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial. [2010.03.30]

Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs. [2010.02]

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. [2008.10.21]

Prostacyclin (epoprostenol) induces headache in healthy subjects. [2008.09.30]

Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. [2007.09]

Transition from intravenous epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. [2007.03.30]

Small-dose epoprostenol decreases systemic oxygen consumption and splanchnic oxygen extraction during normothermic cardiopulmonary bypass. [2006.01]

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. [2004.09]

Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. [2003.03]

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. [2003.02]

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. [2000.03.21]

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). [1999.07]

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). [1997.07]

Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. [1997.03.18]

The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial. [1996.08]

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. [1996.02.01]

Epoprostenol increases plasma level of atrial natriuretic peptide in humans. [1996.02]

Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. [1995.01.19]

Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. [1994.01]

A comparative study of the use of epoprostenol and dihydralazine in severe hypertension in pregnancy. [1992.09]

Effects of vasopressor agents and epoprostenol on systemic hemodynamics and oxygen transport in fulminant hepatic failure. [1992.06]

Comparison between prostaglandin E1 and epoprostenol (prostacyclin) in infants after heart surgery. [1991.08]

Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis. [1991]

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. [1990.04.01]

Epoprostenol (prostacyclin) in unstable angina. [1988.04]

Well-designed clinical trials possibly related to Flolan (Epoprostenol)

Cutaneous iontophoresis of treprostinil in systemic sclerosis: a proof-of-concept study. [2014]

Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients. [2014]

Effects of continuous prostacyclin infusion on regional blood flow and cerebral vasospasm following subarachnoid haemorrhage: statistical analysis plan for a randomized controlled trial. [2014]

Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. [2013]

The effect of oral prostaglandin analogue on painful diabetic neuropathy: a double-blind, randomized, controlled trial. [2013]

The Scottish-Finnish-Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. [2011.04]

Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. [2011]

Beraprost sodium, an orally active prostaglandin I(2) analog, improves renal anemia in hemodialysis patients with peripheral arterial disease. [2010.10]

The effect of consuming meat enriched in walnut paste on platelet aggregation and thrombogenesis varies in volunteers with different apolipoprotein A4 genotype. [2010.09]

Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). [2010.08.04]

Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. [2010.07]

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. [2010.05.04]

Sildenafil and beraprost combination therapy in patients with pulmonary hypertension undergoing valvular heart surgery. [2010.05]

Effect of marine collagen peptides on markers of metabolic nuclear receptors in type 2 diabetic patients with/without hypertension. [2010.04]

Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. [2010.03.02]

Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. [2010.02]

Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. [2010.01]

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. [2010]

Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. [2010]

A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. [2009.12]

Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. [2009.12]

Prostacyclin treatment in severe traumatic brain injury: a microdialysis and outcome study. [2009.08]

Effects of beraprost sodium, an oral prostaglandin i2 analog, on hemostatic factors and inflammation in chronic peritoneal dialysis patients. [2009.03]

Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. [2009.02]

Prostacyclin and thromboxane levels in women with severe preeclampsia undergoing magnesium sulfate therapy during antepartum and postpartum periods. [2008]

Treprostinil for pulmonary hypertension. [2008]

A comparison of hormone therapies on the urinary excretion of prostacyclin and thromboxane A2. [2008]

A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. [2008]

The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. [2007.10.09]

Evidence-based pharmacologic management of pulmonary arterial hypertension. [2007.10]

Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers. [2007.08]

Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction. [2007.06]

Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. [2006.12]

Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. [2006.10.17]

An evidence-based approach to the management of pulmonary arterial hypertension. [2006.07]

Autoregulation of human jejunal mucosal perfusion during cardiopulmonary bypass. [2006.06]

Prostaglandin I2 release following mesenteric traction during abdominal surgery is mediated by cyclooxygenase-1. [2006.05.01]

Effects of oral beraprost sodium, a prostaglandin I2 analogue, on endothelium dependent vasodilatation in the forearm of patients with coronary artery disease. [2006.04]

A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. [2006.03]

Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. [2006.02]

Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors. [2006]

Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. [2005.10]

Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects. [2005.10]

Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension. [2005.09]

Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. [2005.03]

Survival with first-line bosentan in patients with primary pulmonary hypertension. [2005.02]

Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes. [2005]

Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders. [2004.12]

Prostacyclin reduces incidence of myocardial damage after coronary endarterectomy. [2004.10]

Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. [2004.08]

Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. [2004.08]

Prostanoid therapy for pulmonary arterial hypertension. [2004.06.16]

Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. [2004.04]

Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. [2004.02.18]

Effects of d-003, a new substance purified from sugar cane wax, on platelet aggregation and plasma levels of arachidonic acid metabolites in healthy volunteers. [2004]

Platelet aggregation, thromboxane production and thrombogenic ratio in postmenopausal women consuming high oleic acid-sunflower oil or palmolein. [2003.12]

Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not? [2003.11]

Effect of a triclosan-containing dental gel on the levels of prostaglandin I2 and interleukin-1beta in gingival crevicular fluid from adolescents with fixed orthodontic appliances. [2003.08]

Beraprost therapy for pulmonary arterial hypertension. [2003.06.18]

Differences in the effects of extended-release aspirin and plain-formulated aspirin on prostanoids and nitric oxide in healthy volunteers. [2003.06]

Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. [2003.06]

Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. [2003.05.21]

Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis. [2003.05]

Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration. [2003.03]

Prostacyclin reduces symptoms and sympathetic dysfunction in erythromelalgia in a double-blind randomized pilot study. [2003]

Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. [2003]

Effect of long-term administration of prostaglandin I(2) in incipient diabetic nephropathy. [2002.12]

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. [2002.09.21]

Elastase release following myocardial ischemia during extracorporeal circulation (ECC) -- marker of ongoing systemic inflammation? [2002.06]

Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. [2002.06]

[Long-term treatments for systemic sclerosis: what are the perspectives?] [2002.06]

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. [2002.05.01]

Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. [2002.04.03]

Effect of lower body negative pressure against orthostatic intolerance induced by 21 days head-down tilt bed rest. [2002.04]

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. [2002.03.15]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017